Display options
Cite
Diab N, Clark G, Langer L, et al. Impact of race and tumor subtype on second malignancy risk in women with breast cancer. Springerplus. 2016;5:14doi: 10.1186/s40064-015-1657-4.
Diab, N., Clark, G., Langer, L., Wang, Y., Hamlington, B., Brzeskiewicz, L., O'Shaughnessy, J., Diab, S., & Jabbour, S. K. (2016). Impact of race and tumor subtype on second malignancy risk in women with breast cancer. SpringerPlus, 514. https://doi.org/10.1186/s40064-015-1657-4
Diab, Nicholas, et al. "Impact of race and tumor subtype on second malignancy risk in women with breast cancer." SpringerPlus vol. 5 (2016): 14. doi: https://doi.org/10.1186/s40064-015-1657-4
Diab N, Clark G, Langer L, Wang Y, Hamlington B, Brzeskiewicz L, O'Shaughnessy J, Diab S, Jabbour SK. Impact of race and tumor subtype on second malignancy risk in women with breast cancer. Springerplus. 2016 Jan 06;5:14. doi: 10.1186/s40064-015-1657-4. eCollection 2016. PMID: 26759753; PMCID: PMC4703603.
Copy Download .nbib Format: NLM
Share it on

Springerplus. 2016 Jan 06;5:14. doi: 10.1186/s40064-015-1657-4. eCollection 2016.

Impact of race and tumor subtype on second malignancy risk in women with breast cancer.

SpringerPlus

Nicholas Diab, Gary Clark, Lucy Langer, Yunfei Wang, Barbara Hamlington, Laura Brzeskiewicz, Joyce O'Shaughnessy, Sami Diab, Salma K Jabbour

Affiliations

  1. Vanderbilt University, Nashville, TN USA.
  2. Array BioPharma, Inc., Boulder, CO USA.
  3. Genetic Risk Evaluation and Testing Program, Compass Oncology, Portland, OR USA.
  4. Texas Children Hospital, Houston, TX USA.
  5. Genetic Risk Evaluation and Testing Program, Rocky Mountain Cancer Centers, Denver, CO USA.
  6. Baylor Charles A. Sammons Cancer Center, Texas Oncology, US Oncology, Dallas, TX USA.
  7. Rutgers Cancer Institute of New Jersey Rutgers, Rutgers Robert Wood Johnson Medical School, New Brunswick, NJ USA.

PMID: 26759753 PMCID: PMC4703603 DOI: 10.1186/s40064-015-1657-4

Abstract

PURPOSE: Women with breast cancer are at increased risk of second malignancy (SM). However, the impact of race and the hormone receptor (HR) status of the primary breast tumor on risk of SM are not known. The purpose of this study is to analyze the incidence of SM in women with a history of breast cancer according to race and HR status.

METHODS: In the surveillance, epidemiology, and end results database, multiple primary standardized incidence ratio sessions were used to compare the incidence of SM in women with a history breast cancer to the cancer incidence in the general population. Analyses of SM by age, race, and hormone-receptor status were performed using the absolute excess risk (AER) and observed/expected (O/E) ratio.

RESULTS: Younger black women (under the age of 50) were at greater risk of SM with an AER = 76.03 (O/E = 2.3, 95 % CI = 12.19-2.4) compared to younger white women who had an AER = 38.59 (O/E = 1.55, 95 % CI = 1.53-1.58). Older black women (50 years and older) had at an increased risk of SM with an AER = 42.26 (O/E = 1.3, 95 % CI = 1.26-1.34) compared to older white women who had an AER = 11.56 (O/E = 1.07, 95 % CI = 1.06-1.08). Second breast malignancy is the predominant SM in both black and white women. Women with hormone-receptor (HR)-negative breast cancer had higher risk of SMs with an AER = 43.53 (O/E = 1.41, 95 % CI = 1.38- 0.145-3.31) compared to women with HR-positive disease with an AER = 21.43 (O/E = 1.17, 95 % CI = 1.16-0.1.18). In HR-negative women, younger black women had an AER = 96.46 (O/E = 2.99, 95 % CI = 2.70-3.31), younger white women had an AER = 66 (O/E = 2.25, 95 % CI = 2.13-2.36), older black women had an AER = 58.58 (O/E = 1.45, 95 % CI = 1.34-1.57), and older white women had an AER = 20.88 (O/E = 1.14, 95 % CI = 1.11-1.18).

CONCLUSIONS: Black breast cancer survivors and women with HR-negative breast cancer are at increased risk of SM, which deserves further evaluation to understand the biological and clinical basis for this increased risk.

References

  1. Mol Oncol. 2008 Dec;2(4):296-316 - PubMed
  2. Lancet. 2014 Aug 30;384(9945):755-65 - PubMed
  3. Breast Cancer Res. 2010;12(6):R99 - PubMed
  4. J Clin Oncol. 2008 Mar 10;26(8):1239-46 - PubMed
  5. Cancer. 2015 Jan 1;121(1):25-33 - PubMed
  6. Lancet. 2008 Feb 16;371(9612):569-78 - PubMed
  7. Breast Cancer Res. 2014 Jun 03;16(3):211 - PubMed
  8. JAMA. 2005 Oct 19;294(15):1925-33 - PubMed
  9. CA Cancer J Clin. 2015 May-Jun;65(3):221-38 - PubMed
  10. JAMA. 2015 Jan 13;313(2):165-73 - PubMed
  11. Int J Cancer. 2006 May 1;118(9):2285-92 - PubMed
  12. JAMA. 2005 Oct 12;294(14):1765-72 - PubMed
  13. Gynecol Oncol. 2015 Jan;136(1):158-71 - PubMed
  14. Cancer. 2003 Jan 1;97(1 Suppl):211-21 - PubMed
  15. JAMA. 2007 Dec 26;298(24):2869-76 - PubMed
  16. Br J Cancer. 2010 Jan 5;102(1):220-6 - PubMed

Publication Types